MedTrace Logo

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

NCT04906096 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-06-26

No results posted yet for this study

Summary

This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

Conditions

Interventions

DRUG

PAXALISIB

Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol

Sponsors & Collaborators

  • Kazia Therapeutics Limited

    collaborator INDUSTRY

  • Lakshmi Nayak, MD

    lead OTHER

Principal Investigators

  • Lakshmi Nayak, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2026-12-01
Completion
2027-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906096 on ClinicalTrials.gov